Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer
Autore:
Niwa, Y; Akamatsu, H; Niwa, H; Sumi, H; Ozaki, Y; Abe, A;
Indirizzi:
Niwa Inst Immunol, Tosasimizu 7870303, Japan Niwa Inst Immunol Tosasimizu Japan 7870303 ol, Tosasimizu 7870303, Japan Kansai Med Univ, Dept Dermatol, Moriguchi, Osaka 5708507, Japan Kansai MedUniv Moriguchi Osaka Japan 5708507 guchi, Osaka 5708507, Japan Hyogo Prefectural Amagasaki Hosp, Dept Gynecol, Amagasaki, Hyogo 6600828, Japan Hyogo Prefectural Amagasaki Hosp Amagasaki Hyogo Japan 6600828 828, Japan Yamanashi Med Univ, Dept Clin & Lab Med, Yamanashi 4093898, Japan Yamanashi Med Univ Yamanashi Japan 4093898 Med, Yamanashi 4093898, Japan Sumitomo Met Biosci Inc, Res & Dev, Sagamihara, Kanagawa 2290004, Japan Sumitomo Met Biosci Inc Sagamihara Kanagawa Japan 2290004 2290004, Japan
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 2, volume: 7, anno: 2001,
pagine: 285 - 289
SICI:
1078-0432(200102)7:2<285:COTAPR>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
EPIDERMAL LANGERHANS CELLS; FC-EPSILON-RI; ATOPIC-DERMATITIS; HUMAN PLATELETS; CHEMOKINE EXPRESSION; ATONIC DERMATITIS; LESIONAL SKIN; MESSENGER-RNA; T-CELL; IGE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Niwa, Y Niwa Inst Immunol, 4-4 Asahimachi, Tosasimizu 7870303, Japan Niwa Inst Immunol 4-4 Asahimachi Tosasimizu Japan 7870303 , Japan
Citazione:
Y. Niwa et al., "Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer", CLIN CANC R, 7(2), 2001, pp. 285-289

Abstract

The beta -chemokine RANTES was measured in plasma in 43 patients with breast cancer and in 23 patients with cervical cancer, and the RANTES content in primary tumors, tumor metastatic to lymph nodes, and clinically normal skin or pelvic mucosa was measured. In addition, plasma levels were determined in all of the patients for the platelet-derived chemokine beta -thromboglobulin (beta -TG) and for IFN-gamma, interleukin (IL)-2, IL-4, IL-5, and IL-10, along with serum IgE levels and blood eosinophils. Plasma RANTES levels were found to be higher in order of stages IV, III, II, and I of each cancer except for stage I. A marked increase in plasma RANTES level (>10,000 pg/ml) was found in 27% of patients with progressive malignancy but in none of those in clinical remission. The platelet RANTES content was correspondingly decreased in those patients with increased plasma RANTES levels, P-TG showed a pattern similar to RANTES both in plasma and platelets, but with much less dramatic differences between patients with different stages of disease. Other allergic parameters, IgE, eosinophils and plasma IFN-gamma, IL-2, -5, and -10, were not elevated in the cancer patients, The RANTES content was markedly elevated in the primary tumor and metastatic lesions (lymph node or skin) from all of the patients with breast or cervical cancer, irrespective of the plasma RANTES level. In addition, in patients with progressive breast or cervical cancer, but not in patients thought to be cured of these tumors, the RANTES content was markedly increased in clinically normaltissue taken from near the operative site several months postoperatively, as well as in intact skin or mucosa taken perioperatively near the excised tumor. This study suggests an as-yet-undefined but important role played byRANTES in carcinogenesis, as well as the possibility that a RANTES assay in tissue surrounding a tumor or postoperative tumor site may help predict prognosis in these patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 16:33:44